Can a new pill help the immune system fight cancer?

NCT ID NCT07749586

Recruiting now Disease control Sponsor: Arvinas Inc. Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an immunotherapy drug. The goal is to see if the treatment is safe and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARV-6723 (an investigational oral drug) alone or in combination with pembrolizumab (an immunotherapy)
What this could lead to: If ARV-6723 helps the immune system attack cancer cells, it could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is the first human study of ARV-6723, so its safety and effectiveness are unknown. The trial is early-stage and may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal neoplasm cutaneous neuroendocrine carcinoma Esophageal Neoplasms gastric neoplasm hepatocellular carcinoma hereditary sensory and autonomic neuropathy melanoma nasopharyngeal carcinoma neoplasm non-small cell lung carcinoma ovarian cancer renal cell carcinoma small cell lung carcinoma transitional cell carcinoma triple-negative breast carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Clinical Trial Site
RECRUITING

Huntersville, North Carolina, 28078, United States
Clinical Trial Site
RECRUITING

San Antonio, Texas, 78229, United States
Clinical Trial Site
RECRUITING

Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.